The Rules of the Road

Slideshow

A review of the rules of the road for doctors, because everyone remembers their first license.

I heard that you recently got your first license. Congratulations!I think everyone remembers when they first received their driver’s license. It marks a time in a teen’s life when feelings of freedom and independence (“See you later, Pops!”) compete with sheer terror (“Was I supposed to turn left there?”) for the right to dominate the psyche of the tenderfoot driver. In my hometown, shortly after we sophomores received the precious slips, some NASCAR wannabes developed an attitude of, shall we say, insouciance toward the lessons learned in driver’s education. Not surprisingly, our local police officers were delighted to itemize our various transgressions to parents, school principals, head coaches, and other unsympathetic ears.Even I, Mr. Caution himself, succumbed to the temptation to inflate my stock with the cool kids by screeching around the city streets. One night while joyriding with a car full of buddies, I hit the side of a bank-at three miles an hour, no less-a feat that requires a hitherto unknown talent for clumsiness. Thus, I was immortalized in the Gallery of Nincompoops, Vehicular Wing.Pardon? Oh, you just received your medical license. My apologies; here I am rambling on about how to start your motoring career. Wait, though-don’t leave just yet. If we think about it, medicine and driving have several principles in common. Please, take a backseat and review the rules of the road for doctors with me.Artwork by Jon Carter, Cartertoons.com 

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content